$CARM
Carisma Therapeutics Inc

2017 Q2 Form 10-Q Financial Statement

#000148500317000048 Filed on May 04, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $229.0K
YoY Change -100.0% -100.0% -6.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.240M $2.210M $2.150M
YoY Change -35.45% 2.79% -17.31%
% of Gross Profit
Research & Development $2.909M $2.874M $4.632M
YoY Change -11.8% -37.95% -11.57%
% of Gross Profit
Depreciation & Amortization $90.00K $80.00K $50.00K
YoY Change 125.0% 60.0% -50.0%
% of Gross Profit
Operating Expenses $7.350M $6.587M $6.779M
YoY Change 8.58% -2.83% -13.54%
Operating Profit -$7.350M -$6.162M -$6.550M
YoY Change 13.22% -5.92% -13.78%
Interest Expense $0.00 $0.00 -$247.0K
YoY Change -100.0% 5.11%
% of Operating Profit
Other Income/Expense, Net $34.00K $101.0K -$1.024M
YoY Change 3300.0% -109.86% -195.43%
Pretax Income -$7.320M -$6.060M -$7.570M
YoY Change 12.79% -19.95% 16.1%
Income Tax
% Of Pretax Income
Net Earnings -$7.316M -$6.061M -$7.574M
YoY Change 12.71% -19.98% 16.09%
Net Earnings / Revenue -3307.42%
Basic Earnings Per Share -$0.39
Diluted Earnings Per Share -$296.5K -$246.2K -$0.39
COMMON SHARES
Basic Shares Outstanding 24.70M shares 24.70M shares 19.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.80M $20.30M $13.40M
YoY Change 85.88% 51.49% -70.55%
Cash & Equivalents $15.75M $20.27M $13.42M
Short-Term Investments
Other Short-Term Assets $700.0K $700.0K $400.0K
YoY Change 75.0% 75.0% -33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $16.46M $20.98M $13.81M
YoY Change 86.3% 51.96% -70.08%
LONG-TERM ASSETS
Property, Plant & Equipment $632.0K $714.0K $353.0K
YoY Change 101.27% 102.27% -16.35%
Goodwill $17.37M $16.86M
YoY Change
Intangibles $60.50M $60.50M
YoY Change
Long-Term Investments
YoY Change
Other Assets $77.00K $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $78.59M $78.09M $527.0K
YoY Change 18050.12% 14717.46% 19.77%
TOTAL ASSETS
Total Short-Term Assets $16.46M $20.98M $13.81M
Total Long-Term Assets $78.59M $78.09M $527.0K
Total Assets $95.05M $99.07M $14.33M
YoY Change 925.66% 591.19% -69.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.245M $1.214M $1.588M
YoY Change -32.88% -23.55% -22.27%
Accrued Expenses $2.492M $1.897M $491.0K
YoY Change 116.13% 286.35% -63.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.855M $3.226M $2.282M
YoY Change 28.16% 41.37% -50.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $148.0K $46.60M $81.00K
YoY Change 102.74% 57430.86% 24.62%
Total Long-Term Liabilities $148.0K $46.60M $81.00K
YoY Change 102.74% 57430.86% 24.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.855M $3.226M $2.282M
Total Long-Term Liabilities $148.0K $46.60M $81.00K
Total Liabilities $4.003M $66.20M $2.363M
YoY Change 29.93% 2701.52% -49.8%
SHAREHOLDERS EQUITY
Retained Earnings -$136.7M -$129.4M -$132.8M
YoY Change -1.86% -2.54% 35.11%
Common Stock $25.00K $25.00K $20.00K
YoY Change 25.0% 25.0% 11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.91M $32.91M $11.97M
YoY Change
Total Liabilities & Shareholders Equity $95.05M $99.07M $14.33M
YoY Change 925.66% 591.19% -69.23%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$7.316M -$6.061M -$7.574M
YoY Change 12.71% -19.98% 16.09%
Depreciation, Depletion And Amortization $90.00K $80.00K $50.00K
YoY Change 125.0% 60.0% -50.0%
Cash From Operating Activities -$4.510M -$5.195M -$8.550M
YoY Change -9.98% -39.24% 0.83%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$10.00K $80.00K
YoY Change
Cash From Investing Activities -$10.00K $76.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $45.00K -$14.11M
YoY Change -100.0% -100.32%
NET CHANGE
Cash From Operating Activities -4.510M -$5.195M -$8.550M
Cash From Investing Activities -10.00K $76.00K $0.00
Cash From Financing Activities 0.000 $45.00K -$14.11M
Net Change In Cash -4.520M -$5.074M -$22.66M
YoY Change -8.5% -77.61% 166.27%
FREE CASH FLOW
Cash From Operating Activities -$4.510M -$5.195M -$8.550M
Capital Expenditures $0.00
Free Cash Flow -$8.550M
YoY Change 0.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24700746 shares
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
CY2017Q1 dei Trading Symbol
TradingSymbol
EBIO
CY2017Q1 ebio Working Capital Net
WorkingCapitalNet
17800000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1667000 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1214000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1774000 USD
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1897000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
413000 USD
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
178000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
161963000 USD
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162243000 USD
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3530682 shares
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2661741 shares
CY2016Q4 us-gaap Assets
Assets
104097000 USD
CY2017Q1 us-gaap Assets
Assets
99068000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25927000 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
20980000 USD
CY2016Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2017Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1500000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45100000 USD
CY2017Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
46600000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36079000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13419000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25342000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20268000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22660000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5074000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24531964 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24683026 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24531964 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24683026 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2016Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
852000 USD
CY2017Q1 us-gaap Construction Payable Current
ConstructionPayableCurrent
1308000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
425000 USD
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
16335000 USD
CY2017Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
16335000 USD
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
54000 USD
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
82000 USD
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5000 USD
CY2017Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
114000 USD
CY2017Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
115000 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
352000 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
318000 USD
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-115000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3000 USD
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2017Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P11M1D
CY2017Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P8M1D
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.8339
CY2017Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.8142
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0085
CY2017Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0095
CY2016Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2017Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
76000 USD
CY2016Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-915000 USD
CY2017Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2147000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2213000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
16864000 USD
CY2017Q1 us-gaap Goodwill
Goodwill
16864000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
342000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-453000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1645000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
123000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-203000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-425000 USD
CY2016Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
CY2017Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
162000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
127000 USD
CY2016Q1 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
80000 USD
CY2017Q1 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60500000 USD
CY2017Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60500000 USD
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-247000 USD
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
663000 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104097000 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99068000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3980000 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3226000 USD
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
425000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14110000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
76000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8550000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5195000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-7574000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-6061000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1024000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
101000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
6779000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
6587000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6550000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6162000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157000 USD
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
93000 USD
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
138000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
101000 USD
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
585000 USD
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
712000 USD
CY2016Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
76000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40000 USD
CY2016Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 USD
CY2017Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
796000 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
714000 USD
CY2016Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14124000 USD
CY2017Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4632000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2874000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123311000 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129363000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.41
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.22
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129400000 USD
CY2016Q1 us-gaap Revenues
Revenues
229000 USD
CY2017Q1 us-gaap Revenues
Revenues
0 USD
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
229000 USD
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
425000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
586000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
244000 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
863767 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.93
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
166887 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2024468 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1717181 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1717181 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.22
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.28
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.85
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
140400 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
38677000 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
32905000 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19639000 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24610000 shares
CY2016Q1 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
221000 USD
CY2017Q1 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
0 USD

Files In Submission

Name View Source Status
0001485003-17-000048-index-headers.html Edgar Link pending
0001485003-17-000048-index.html Edgar Link pending
0001485003-17-000048.txt Edgar Link pending
0001485003-17-000048-xbrl.zip Edgar Link pending
ebio-033117x10q.htm Edgar Link pending
ebio-033117x311.htm Edgar Link pending
ebio-033117x312.htm Edgar Link pending
ebio-033117x321.htm Edgar Link pending
ebio-20170331.xml Edgar Link completed
ebio-20170331.xsd Edgar Link pending
ebio-20170331_cal.xml Edgar Link unprocessable
ebio-20170331_def.xml Edgar Link unprocessable
ebio-20170331_lab.xml Edgar Link unprocessable
ebio-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending